CII
STML

CR Intrinsic Investors’s Stemline Therapeutics, Inc. STML Stock Holding History

CR Intrinsic Investors’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-76,308
Closed -$3.46M – 391
2013
Q3 		$3.46M Buy
+76,308
New +$2.49M 0.11% 240

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CR Intrinsic Investors's STML Position: Q4 2013 in Review

CR Intrinsic Investors sold out of Stemline Therapeutics, Inc. (STML) in Q4 2013, closing a stake of 76,308 shares — an estimated $3.46M sold.

CR Intrinsic Investors first reported a position in STML in Q3 2013 and held it in 1 quarter. The position peaked at $3.46M in Q3 2013. 69 funds tracked by Wall St. Rank hold STML as of Q4 2013.

  • CR Intrinsic Investors reported no remaining Stemline Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • CR Intrinsic Investors sold 76,308 Stemline Therapeutics, Inc. shares in Q4 2013, an estimated $3.46M.
  • CR Intrinsic Investors first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's Stemline Therapeutics, Inc. position peaked at $3.46M in Q3 2013.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2013.

Based on CR Intrinsic Investors's 13F filing for Q4 2013, filed 14 Feb 2014.